Helixmith Obtains U.S. Patent for CAR-T Cell Therapy Technology
"Expectations for Development of Treatment for Intractable Solid Tumors"
[Asia Economy Reporter Lee Gwanju] Helixmith announced on the 15th that it has obtained a U.S. patent for its 'CAR-T' cell therapy technology targeting 'TAG-72,' which is highly expressed in solid tumors. The patent has been registered in Japan, Europe, and the United States, and is currently awaiting registration in South Korea as well as China, Hong Kong, Australia, and Canada.
This patent pertains to 'cells expressing anti-sialyl Tn chimeric antigen receptors (ANTI-SIALYL TN CHIMERIC ANTIGEN RECEPTORS) and compositions thereof.' It is a CAR-T (Chimeric Antigen Receptor-T) cell therapy that can recognize and exert cytotoxic effects on cancers expressing the sialyl Tn (STn) antigen on the TAG-72 (Tumor Associated Glycoprotein 72) glycoprotein, which is highly expressed in solid tumors.
Helixmith has developed anti-STn CAR-T cells that specifically recognize the STn antigen and confirmed their antitumor effects against cancer cells expressing the STn antigen on the TAG-72 glycoprotein. Cancers that can be treated with anti-STn CAR-T cells include all cancers that overexpress TAG-72. These include various intractable solid tumors such as colorectal cancer, ovarian cancer, gastric cancer, breast cancer, esophageal cancer, bladder cancer, lung cancer, and pancreatic cancer. The company explained that it is expected to be applied as a cancer treatment for these difficult-to-treat cancers.
Hot Picks Today
"Could I Also Receive 370 Billion Won?"... No Limit on 'Stock Manipulation Whistleblower Rewards' Starting the 26th
- Samsung Electronics Labor-Management Reach Agreement, General Strike Postponed... "Deficit-Business Unit Allocation Deferred for One Year"
- "From a 70 Million Won Loss to a 350 Million Won Profit with Samsung and SK hynix"... 'Stock Jackpot' Grandfather Gains Attention
- "Stocks Are Not Taxed, but Annual Crypto Gains Over 2.5 Million Won to Be Taxed Next Year... Investors Push Back"
- "Who Is Visiting Japan These Days?" The Once-Crowded Tourist Spots Empty Out... What's Happening?
Yoo Seungshin, CEO of Helixmith, said, "CAR-T cell therapy is called a miracle anticancer drug and a fourth-generation anticancer drug, and is the most globally recognized gene therapy." He added, "With related patents registered in the U.S., Europe, and Japan, Helixmith's CAR-T therapy platform technology is gaining global recognition. Based on this, we expect that anticancer gene cell therapies for intractable cancers overexpressing TAG-72 can be developed."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
